Investment thesis
Iovance Biotherapeutics (IOVA) stock has jumped 17% this week on news that data from a phase 1 trial evaluating the use of tumor-infiltrating lymphocytes (TIL) in combination with Nivolumab to treat patients with non-small cell lung cancer and other types of solid tumours will be presented at the American Association for Cancer Research on April 28th.
The wording of the announcement has generated a ripple of excitement, since it suggests that some durable Complete Responses (“CR”) have been achieved using the combination that may be an improvement on results that can